| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-12-09 |
| タイトル |
|
|
タイトル |
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
atezolizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
bevacizumab |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Child–Pugh class B |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hepatocellular carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
modified albumin–bilirubin grade |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Sasaki, Ryu
Shimose, Shigeo
Saeki, Issei
Ito, Takanori
Takeuchi, Yasuto
Tani, Joji
Tomonari, Tetsu
Sasaki, Kyo
Kakizaki, Satoru
Hatanaka, Takeshi
Miuma, Satoshi
Shirono, Tomotake
Iwamoto, Hideki
Tanabe, Norikazu
Yamamoto, Takafumi
Kanayama, Yuki
Naganuma, Atsushi
Nishina, Sohji
Takayama, Tetsuji
Kobara, Hideki
Otsuka, Motoyuki
Kawashima, Hiroki
Takami, Taro
Kawaguchi, Takumi
Miyaaki, Hisamitsu
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background & Aims: Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child–Pugh class B (CP-B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP-B. Methods: This retrospective study included 796 patients who received Atez/Bev between October 2020 and July 2024 from 10 institutions in Japan. The median observation period was 14.6 months. The liver function was assessed using the CP classification and modified ALBI (mALBI) grade. The progression-free survival (PFS), overall survival (OS) and median survival time (MST) were evaluated. Results: Patients with CP-B had significantly shorter PFS and OS than those with CP-A (median PFS, 4.6 months vs. 7.0 months; MST, 10.3 months vs. 23.2 months) (PFS, p = 0.009; OS, p < 0.001). Although CP-B was associated with a higher incidence of bleeding-related events, the discontinuation rate due to adverse events did not differ from that of CP-A. As a factor for stratifying CP-B outcomes, significant differences in the PFS, OS and response rate were observed between mALBI grades ≤ 2b and 3 (PFS, p = 0.004; OS, p = 0.024; response rate, p = 0.001). In multivariate analysis, the mALBI grade (hazard ratio [95% CI]: 2.388 [1.186–4.810]; p = 0.014) was extracted as a factor contributing to OS in patients with CP-B. Conclusion: Atez/Bev therapy demonstrated efficacy and safety in patients with CP-B, especially when hepatic reserve is maintained within mALBI grade 2b. |
|
言語 |
en |
| 書誌情報 |
en : Liver International
巻 46,
号 1,
p. art. no. e70466,
発行日 2025-11-28
|
| 出版者 |
|
|
出版者 |
John Wiley & Sons Ltd |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1478-3223 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/liv.70466 |
| 権利 |
|
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2025 The Author(s). Liver International published by John Wiley & Sons Ltd. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Liver International, 46(1), art. no. e70466; 2025 |
|
言語 |
en |
LI46_e70466.pdf (779 KB)
